Clinical trial
Colchicine Titration Guided by Hs-CRP Targets on Cardiovascular Events in Very-High-Risk Coronary Heart Disease Patients After PCI: A Multicenter, Randomized, Open-Label, Noninferiority Trial
NCT07920133 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, 1,768 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital; China. Primary measure: Major Adverse Cardiovascular Events Through 18 Months.
How it compares
370 similar trials: same condition (Atherosclerosis) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Colchicine Titration Guided by Hs-CRP Targets on Cardiovascular Events in Very-High-Risk Coronary Heart Disease Patients After PCI: A Multicenter, Randomized, Open-Label, Noninferiority Trial
- Lead sponsor
- Sir Run Run Shaw Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- December 31, 2032
- Enrollment
- 1,768 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Atherosclerosis, Coronary Artery Disease
Registry terms: atherosclerotic cardiovascular disease (ascvd), residual inflammatory risk
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Sir Run Run Shaw Hospital
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Standard hs-CRP Target (1.0 to <2.0 mg/L) | Experimental | Colchicine (Colcrys®) |
Show registry wordingColchicine 0.25 mg orally once daily at initiation, with hs-CRP-guided adjustments to target 1.0 to \<2.0 mg/L. At 1 month, reduce to 0.25 mg every other day if hs-CRP \<1.0 mg/L; maintain 0.25 mg daily if 1.0 to \<2.0 mg/L; or, if tolerated, increase to 0.5 mg daily if ≥2.0 mg/L. If the target remains unmet after one month at 0.5 mg daily, stop protocol-directed colchicine and continue endpoint/safety follow-up. Dose reduction or discontinuation is permitted for adverse reactions. | ||
| Intensive hs-CRP Target (<1.0 mg/L) | Active comparator | Colchicine (Colcrys®) |
Show registry wordingColchicine 0.25 mg orally once daily at initiation, with hs-CRP-guided adjustments to target \<1.0 mg/L. At 1 month, maintain 0.25 mg daily if hs-CRP \<1.0 mg/L; otherwise, if tolerated, increase to 0.5 mg daily. If the target remains unmet after one month at 0.5 mg daily, stop protocol-directed colchicine and continue endpoint/safety follow-up. Dose reduction or discontinuation is permitted for adverse reactions. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Major Adverse Cardiovascular Events Through 18 Months | From randomization through 18 months |
Show registry wordingTime to first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or ischemia-driven coronary revascularization. The primary noninferiority comparison is the hazard ratio for the standard hs-CRP target strategy versus the intensive hs-CRP target strategy, with a prespecified margin of 1.30; events are adjudicated by an independent blinded clinical events committee. | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Colchicine
- US 10226423; expires December 20, 2037; assignee RxOmeg Therapeutics LLC
- US 10383820; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
- US 10383821; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
- US 12274751; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
- US 12514819; expires November 22, 2036; assignee not stated
- +36 more patents
Lead sponsor's other trials
Sir Run Run Shaw Hospital, most recent start first.
+129 more trials See the organization page
Similar trials
Same condition (Atherosclerosis) and phase, most recent start first.
+365 more trials See the condition page